title: Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease.
abstract: BACKGROUND
  Perampanel is a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor antagonist. Two multicenter randomized, double-blind, placebo-controlled, parallel-group phase III studies assessed the efficacy and safety of adjunctive perampanel in patients with Parkinson's disease and motor fluctuations.
  
  
  METHODS
  In both phase III studies (301 and 302), levodopa-treated patients were randomized and treated with once-daily oral placebo (n = 504), perampanel 2 mg (n = 509), or perampanel 4 mg (n = 501). The primary end point was change in daily "off" time from baseline. The treatment period was 30 weeks in study 301 and 20 weeks in study 302.
  
  
  RESULTS
  For any efficacy end point, perampanel 2 or 4 mg was not superior to placebo. Perampanel was well tolerated up to 4 mg/day.
  
  
  CONCLUSIONS
  Perampanel failed to significantly improve motor symptoms versus placebo. There was also no effect on the duration or disability of levodopa-induced dyskinesia.
authors.affiliation: Reta Lila Weston Institute for Neurological Studies, University College London, London, UK. alees@ion.ucl.ac.uk
authors.forename: Andrew
authors.initials: A
authors.lastname: Lees
authors.forename: Stanley
authors.initials: S
authors.lastname: Fahn
authors.forename: Karla M
authors.initials: KM
authors.lastname: Eggert
authors.forename: Joseph
authors.initials: J
authors.lastname: Jankovic
authors.forename: Anthony
authors.initials: A
authors.lastname: Lang
authors.forename: Federico
authors.initials: F
authors.lastname: Micheli
authors.forename: M Maral
authors.initials: MM
authors.lastname: Mouradian
authors.forename: Wolfgang H
authors.initials: WH
authors.lastname: Oertel
authors.forename: C Warren
authors.initials: CW
authors.lastname: Olanow
authors.forename: Werner
authors.initials: W
authors.lastname: Poewe
authors.forename: Olivier
authors.initials: O
authors.lastname: Rascol
authors.forename: Eduardo
authors.initials: E
authors.lastname: Tolosa
authors.forename: David
authors.initials: D
authors.lastname: Squillacote
authors.forename: Dinesh
authors.initials: D
authors.lastname: Kumar
mesh_terms: D000368:Aged; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009570:Nitriles; D010300:Parkinson Disease / Q000188:drug therapy*; D011728:Pyridones / Q000627:therapeutic use*
chemical_list: D018691:Excitatory Amino Acid Antagonists; D009570:Nitriles; D011728:Pyridones; C551441:perampanel